Schematic of Study Design.
CML-CP
CHRONIC MYELOID LEUKEMIA
ATP: adenosine triphosphate, BID: twice daily, CML-CP: chronic myeloid leukemia in chronic phase, QD: once daily, TKI: tyrosine kinase inhibitor Switch to asciminib allowed for bosutinib-treated patients meeting the lack of efficacy criteria based on the 2013 European LeukemiaNet recommendations for second-line TKI therapy [